| Literature DB >> 32562119 |
Michelle Specht1,2, Nikhil Sobti3, Nikki Rosado3, Eleanor Tomczyk3, Olivia Abbate3, Dan Ellis3,2, Eric C Liao4,5.
Abstract
PURPOSE: As our hospitals conserve and re-allocate resources during the COVID-19 crisis, there is urgent need to determine how best to continue caring for breast cancer patients. During the time window before the COVID-19 critical peak and particularly thereafter, as hospitals are able to resume cancer operations, we anticipate that there will be great need to maximize efficiency to treat breast cancer. The goal of this study is to present a same-day protocol that minimizes resource utilization to enable hospitals to increase inpatient capacity, while providing care for breast cancer patients undergoing mastectomy and immediate breast reconstruction during the COVID-19 crisis.Entities:
Keywords: Breast reconstruction; COVID-19; Coronavirus; Protocol; Same-day
Mesh:
Year: 2020 PMID: 32562119 PMCID: PMC7304917 DOI: 10.1007/s10549-020-05739-7
Source DB: PubMed Journal: Breast Cancer Res Treat ISSN: 0167-6806 Impact factor: 4.872
Fig. 1Inclusion criteria for patients selected for same-day mastectomy and immediate breast reconstruction
Fig. 2Same-day mastectomy and immediate breast reconstruction protocol, modified in the setting of COVID-19 to convert in-person pre-operative and postoperative evaluations to online visits. Importantly, drain management and removal are facilitated by visiting nursing services in an attempt to minimize nosocomial viral exposure and decrease resource utilization
Fig. 3Peri-operative checklist for the same-day mastectomy and immediate breast reconstruction protocol
Clinical characteristics
| Patient characteristics | |
|---|---|
| Patient demographics | 15 |
| Average age ± SD, years | 45.20 ± 7.06 |
| BMI ± SD, kg/m2 | 24.80 ± 4.58 |
| Smoking | 0 (0.00) |
| Diabetes | 0 (0.00) |
| Obese | 2 (13.33) |
| Neoadjuvant chemotherapy | 3 (20.00) |
| Prior radiation | 1 (6.67) |
| Oncologic characteristicsa | |
| BRCA carrier | 1 (6.67) |
| PALB2 carrier | 0 (0.00) |
| PTEN carrier | 0 (0.00) |
| Negative genetic testing | 8 (53.33) |
| IDCb | 8 (42.11) |
| Grade 1 | 2 (25.00) |
| Grade 2 | 2 (25.00) |
| Grade 3 | 4 (50.00) |
| DCISb | 15 (78.95) |
| Grade 1 | 0 (0.00) |
| Grade 2 | 5 (33.33) |
| Grade 3 | 10 (66.67) |
| T-size | |
| T1 | 9 (60.00) |
| T2 | 3 (20.00) |
| T3 | 2 (13.33) |
| Unknown | 1 (6.67) |
| Nodal status | |
| N0 | 9 (60.00) |
| N1 | 1 (6.67) |
| N2 | 2 (13.33) |
| N3 | 1 (6.67) |
| Unknown | 2 (13.33) |
| Sentinel node biopsy | 11 (73.33) |
| Axillary lymph node dissection | 3 (20.00) |
| Procedure laterality | |
| Unilateral | 11 (73.33) |
| Bilateral | 4 (26.67) |
| Implant placementb | |
| Pre-pectoral | 11 (57.90) |
| Subpectoral | 8 (42.10) |
| Mastectomy type | |
| Skin-Sparing | 4 (26.67) |
| Nipple-Sparing | 11 (73.33) |
| Reconstruction stageb | |
| Single-stage (DTI) | 11 (57.90) |
| Two-stage (TE) | 8 (42.10) |
SD standard deviation, BMI body mass index, IDC invasive ductal carcinoma, DCIS ductal carcinoma in-situ, DTI direct-to-implant, TE tissue expander
aGiven variability in time interval of pathologic evaluation, oncotype for 4 cases were recorded per core needle biopsy. Additionally, genetic testing results were for 4 patients were unknown given short follow-up duration
bDenotes data presented by breast (n = 19)
Efficacy outcomes for same-day immediate breast reconstruction
| Efficacy endpoints | |
|---|---|
| Mean operative time ± SD, minutes | 151.27 ± 33.14 |
| Mean time interval to discharge ± SD, minutes | 301.27 ± 77.13 |
| Re-admissions | 0 (0.00) |
| Emergency department visits | 0 (0.00) |
SD standard deviation